West Pharmaceutical Services Inc (New York Stock Exchange:WST)
| Market Cap | 25.51B+36.8% |
| Revenue (ttm) | 3.33B+12.4% |
| Net Income | 564.90M+15.8% |
| EPS | 7.82+17.1% |
| Shares Out | 70.38M |
| PE Ratio | 46.05 |
| Forward PE | 36.21 |
| Dividend | $0.88(0.24%) |
| Ex-Dividend Date | Jul 29, 2026 |
| Volume | 18,888 |
| Open | 365.65 |
| Previous Close | 366.48 |
| Day's Range | 362.03 - 367.39 |
| 52-Week Range | 223.83 - 386.00 |
| Beta | 1.13 |
| Analysts | Buy |
| Price Target | 419.50(+15.75%) |
| Earnings Date | Oct 22, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About WST
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$WST stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of WST by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Jared MoskowitzHouse / D | Sale$1.00K – $15.00K | Feb 13, 2025 |
| Jared MoskowitzHouse / D | Sale$1.00K – $15.00K | Feb 12, 2025 |
| Jared MoskowitzHouse / D | Sale$1.00K – $15.00K | Nov 8, 2024 |
| Jared MoskowitzHouse / D | Sale$1.00K – $15.00K | Nov 7, 2024 |
| Jared MoskowitzHouse / D | Purchase$1.00K – $15.00K | Dec 28, 2023 |
| Jared MoskowitzHouse / D | Purchase$1.00K – $15.00K | Dec 27, 2023 |
| Jared MoskowitzHouse / D | Purchase$1.00K – $15.00K | Jul 14, 2023 |
| Jared MoskowitzHouse / D | Purchase$1.00K – $15.00K | Jul 13, 2023 |
Recently reported changes in WST holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by WST's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
WST Estimated quarterly lobbying spending
Source: U.S. Senate LDA
WST Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Proprietary Products | $722.60M | 82.84% |
| West Vantage | $149.70M | 17.16% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New WST patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to WST from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in WST
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $765.75M |
| VOOVanguard S&P 500 ETF | $640.24M |
| VOVanguard Morningstar Mid-Cap ETF | $521.26M |
| IVViShares Core S&P 500 ETF | $349.46M |
| SPYState Street SPDR S&P 500 ETF | $320.57M |
| VUGVanguard Morningstar Growth ETF | $318.14M |
Estimated from each fund’s disclosed top holdings × AUM
WST Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from WST’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score